Menopausal hormone therapy: cardiovascular outcomes and the timing window for individualized treatment
DOI:
https://doi.org/10.62827/fb.v27i10.1371Keywords:
Climacteric; Atherosclerosis; Cardiovascular Diseases; Venous Thromboembolism; Decision Making.Abstract
Introduction: Menopausal hormone therapy is an effective treatment for vasomotor symptoms, although its cardiovascular effects depend on patient characteristics and therapeutic regimens. Objective: This integrative review aimed to analyze the cardiovascular effects of systemic menopausal hormone therapy, the timing hypothesis, and factors associated with treatment individualization. Methods: Searches were considered in PubMed/MEDLINE, Scopus, and Web of Science through October 16, 2026, focusing on randomized clinical trials evaluating cardiovascular events or objective vascular markers. A total of 695 records were identified, and 18 publications were considered eligible, representing 16 independent randomized trials. Results: The findings did not demonstrate consistent cardiovascular benefits of hormone therapy for primary or secondary prevention. Certain oral regimens were associated with increased risks of stroke and venous thromboembolism. Evidence regarding the timing hypothesis was heterogeneous, with conflicting findings on atherosclerosis progression among recently postmenopausal women. The interpretation of benefits and risks depends on age, time since menopause, hormonal formulation, route of administration, and individual cardiovascular risk. Conclusion: The analyzed trials do not support menopausal hormone therapy for cardiovascular prevention. Indications for symptom management in selected women and criteria for treatment individualization are supported by complementary clinical guidelines, with benefit-risk assessment and periodic reassessment.
References
The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028.
Lumsden MA, Dekkers OM, Faubion SS, et al. European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur J Endocrinol. 2025;193(4):G49-G81. doi:10.1093/ejendo/lvaf206.
Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321.
Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. doi:10.1001/jama.291.14.1701.
Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477. doi:10.1001/jama.297.13.1465.
Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231. doi:10.1056/NEJMoa1505241.
Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249-260. doi:10.7326/M14-0353.
Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. doi:10.1136/bmj.e6409.
Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546-553. doi:10.1111/j.1365-2648.2005.03621.x.
Souza MT, Silva MD, Carvalho R. Revisão integrativa: o que é e como fazer. Einstein (Sao Paulo). 2010;8(1 Pt 1):102-106. doi:10.1590/S1679-45082010RW1134.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605-613. doi:10.1001/jama.280.7.605.
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345(17):1243-1249. doi:10.1056/NEJMoa010534.
Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343(8):522-529. doi:10.1056/NEJM200008243430801.
Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288(19):2432-2440. doi:10.1001/jama.288.19.2432.
Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349(6):535-545. doi:10.1056/NEJMoa030830.
Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135(11):939-953. doi:10.7326/0003-4819-135-11-200112040-00005.
Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360(9350):2001-2008. doi:10.1016/S0140-6736(02)12001-0.
Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239. doi:10.1136/bmj.39266.425069.AD.
Høibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000;84(6):961-967. PMID:11154141.
Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. BJOG. 2002;109(9):1056-1062. doi:10.1111/j.1471-0528.2002.01544.x.
Veerus P, Hovi SL, Fischer K, et al. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas. 2006;55(2):162-173. doi:10.1016/j.maturitas.2006.01.012.
Boardman HMP, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229. doi:10.1002/14651858.CD002229.pub4.
Gu Y, Han F, Xue M, Wang M, Huang Y. The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis. BMC Womens Health. 2024;24(1):60. doi:10.1186/s12905-023-02788-0.
Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-2602. doi:10.1056/NEJMoa071513.
Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040.
Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49-57. doi:10.1001/jama.288.1.49.
Bencivenga PA, Fort N, Fugh-Berman A, Scialli AR. The effects of menopausal hormone therapy on cardiovascular disease, cancer, cognition and depression in younger women: a systematic review. JRSM Open. 2026;17(6):20542704261455970. doi:10.1177/20542704261455970.
Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199-208. PMID:7807658.
Oliveira GMM, Almeida MCC, Arcelus CMA, Espíndola LN, Rivera MAM, Silva-Filho AL, et al. Diretriz Brasileira sobre a Saúde Cardiovascular no Climatério e na Menopausa – 2024. Arq Bras Cardiol. 2024;121(7):e20240478. doi:10.36660/abc.20240478.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Katia Azevedo Costa, João Fernando Cloclet Pio da Silva, Marcella Portela Barbosa, João Matheus de Oliveira Santos, Giovanna Valadão de Brito, Paula Venturini Pivotto, Maria Eduarda Silva de Souza, Cristiano Eduardo Antunes (Autor)

This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution 4.0 que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
Autores têm autorização para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.